[1]王晓果,陈婷,刘焕凤,等.小剂量地西他滨在异基因造血干细胞移植后早期复发及cGVHD治疗中的作用[J].第三军医大学学报,2016,38(12):1362-1365.
 Wang Xiaoguo,Chen Ting,Liu Huanfeng,et al.Role of small-dose decitabine in treatment of early recurrence and chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2016,38(12):1362-1365.
点击复制

小剂量地西他滨在异基因造血干细胞移植后早期复发及cGVHD治疗中的作用(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第12期
页码:
1362-1365
栏目:
专题报道
出版日期:
2016-06-30

文章信息/Info

Title:
Role of small-dose decitabine in treatment of early recurrence and chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation
作者:
王晓果陈婷刘焕凤邓天霞刘俊张诚张曦孔佩艳
第三军医大学新桥医院全军血液病中心
Author(s):
Wang XiaoguoChen TingLiu HuanfengDeng TianxiaLiu JunZhang ChengZhang XiKong Peiyan

Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

关键词:
地西他滨异基因造血干细胞移植移植物抗宿主病
Keywords:
decitabine allogeneic hematopoietic stem cell transplantation graft versus host disease
分类号:
R617; R730.53; R733.71
文献标志码:
A
摘要:

目的      分析小剂量地西他滨(decitabine/dacogen,DAC)治疗异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)后慢性移植物抗宿主病(chronic graft versus host disease,cGVHD)患者的转归情况。      方法      收集2013年6月25日至2015年7月7日我院行allo-HSCT术后早期复发及发生cGVHD,并接受小剂量DAC治疗的4例患者,包括急性髓系白血病(acute myeloid leukemia,AML)3例,骨髓增生异常综合征(myelodysplastic syndrome,MDS)1例。对其诊断、移植方式、cGVHD分型及评分、以及DAC治疗后转归进行分析。      结果      4例接受小剂量DAC的患者,cGVHD症状减轻,无严重的血液学毒性。1例因严重肺部感染放弃治疗,3例目前病情稳定。      结论      小剂量DAC可减轻allo-HSCT术后cGVHD症状,改善患者生存质量,并对早期复发的控制有一定的效果。

Abstract:

Objective      To analyze the outcomes of 4 cases of chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) treated by small-dose decitabine/dacogen (DAC).       Methods      Clinical data of 4 patients who have cGVHD effects and early recurrence after allo-HSCT,and then received small-dose DAC treatment in our hospital from June 25,2013 to July 7,2015 were collected in this study. Three of them were acute myeloid leukemia (AML), and the other 1 case was myelodysplastic syndrome (MDS).Their diagnosis, transplantation methods, types and scores of cGVHD, and treatment outcome were retrospectively analyzed.       Results      All 4 patients had decreased effects of cGVHD and had no severe hematologic toxicity after small-dose DCA therapy.One of the patients gave up the treatment because of pulmonary infection, and the other 3 ones were in stable disease stage till now.       Conclusion      Small-dose DAC therapy alleviates cGVHD after allo-HSCT, improves quality of life in the patients,and has certain effect on controlling early recurrence.

参考文献/References:

[1]Suzuki T, Tanaka R, Hamada S, et al. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors [J]. Bioorg Med Chem Lett, 2010, 20(3): 1124-1127. DOI: 10.1016/j.bmcl.2009.12.016
[2]Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes[J]. J Clin Oncol, 2011, 29(5): 516-523. DOI: 10.1200/JCO.2010.31.0854
[3]Oshikawa G, Kakihana K, Saito M, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia[J]. Br J Haematol, 2015, 169(5): 756-759. DOI: 10.1111/bjh.13248
[4]Mufti G J, Potter V. Myelodysplastic syndromes: who and when in the course of disease to transplant[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012: 49-55. DOI: 10.1182/asheducation-2012.1.49
[5]Martino M, Fedele R, Moscato T, et al. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents[J]. Curr Cancer Drug Targets, 2013, 13(6): 661-669.
[6]Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia[J]. Cancer, 2009, 115(9): 1899-1905. DOI: 10. 1002/cncr.24198
[7]Pusic I, Choi J, Fiala M A, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome[J]. Biol Blood Marrow Transplant, 2015, 21(10): 1761-1769. DOI: 10.1016/j.bbmt.2015.05.026
[8]Yang X, Lay F, Han H, et al. Targeting DNA methylation for epigenetic therapy[J]. Trends Pharmacol Sci, 2010, 31(11): 536-546. DOI: 10.1016/j.tips.2010.08.001
[9]Qin T, Youssef E M, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines[J]. Clin Cancer Res, 2007, 13 (14): 4225-4232. DOI: 10.1158/1078-0432.CCR-06-2762
[10]Wang J, Yi Z, Wang S, et al. The effect of decitabine on megakaryocyte maturation and platelet release[J]. Thromb Haemost, 2011, 106(2): 337-343. DOI: 10.1160/TH10-11-0744
[11]Ganguly S, Amin M, Divine C, et al. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)[J]. Ann Hematol, 2013, 92(4): 549-550. DOI: 10.1007/s00277-012-1607-y
[12]Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation[J]. Leukemia, 2013, 27(6): 1229-1235. DOI: 10. 1038/leu.2013.7
[13]Choi J, Ritchey J, Prior J L, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia[J]. Blood, 2010, 116(1): 129-139. DOI: 10.1182/blood-2009-12-257253
[14]Rezvani K, Yong A S, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies[J]. Blood, 2008, 111(1): 236-242. DOI: 10.1182/ blood-2007-08-108241
[15]de-Lima M, Ravandi F, Shahjahan M, et al. Long-term follow-up of a phase Ⅰ study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias[J]. Cancer, 2003, 97(5): 1242-1247. DOI: 10.1002/cncr.11184

相似文献/References:

[1]陈姝,李文,罗云,等.减低剂量Bu+Cy预处理方案进行异基因造血干细胞移植治疗白血病的效果观察[J].第三军医大学学报,2012,34(24):2442.
 Chen Shu,Li Wen,Luo Yun,et al.Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen of Bu+Cy for leukemia[J].J Third Mil Med Univ,2012,34(12):2442.
[2]刘嘉,高蕾,张曦,等.异基因造血干细胞移植联合伊马替尼治疗成人Ph+急性淋巴细胞白血病临床观察[J].第三军医大学学报,2012,34(24):2453.
 Liu Jia,Gao Lei,Zhang Xi,et al.Clinical efficiency of allogenic hematopoietic stem cell transplantation combined with imatinib in treatment of Philadelphia positive acute lymphoblastic leukemia[J].J Third Mil Med Univ,2012,34(12):2453.
[3]苏毅,赖思含,易海,等.异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析[J].第三军医大学学报,2012,34(24):2456.
 Su Yi,Lai Sihan,Yi Hai,et al.Allogeneic hematopoietic stem cell transplantation for recurrent lymphoma after autologous stem cell transplantation: clinical analysis of 17 cases[J].J Third Mil Med Univ,2012,34(12):2456.
[4]梁雪,陈幸华,孔佩艳,等.异基因造血干细胞移植后肠道移植物抗宿主病临床分析[J].第三军医大学学报,2009,31(21):2158.
[5]颜红菊,唐伦,高蕾,等.单倍体与同胞全相合造血干细胞移植治疗高危急性淋巴细胞白血病疗效观察[J].第三军医大学学报,2016,38(12):1340.
 Yan Hongju,Tang Lun,Gao Lei,et al.Efficacy of haploid-matched vs sibling-matched allogeneic stem cell transplantation for high risk acute lymphoblastic leukemia[J].J Third Mil Med Univ,2016,38(12):1340.

更新日期/Last Update: 2016-06-07